113 studies found for:    30607
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
Conditions: Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Recruiting BKM120 for Patients With PI3K-activated Tumors
Condition: PI3K Pathway Activated Tumors
Intervention: Drug: BKM120
3 Active, not recruiting Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: tamoxifen citrate;   Radiation: Radiation Therapy
4 Terminated BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
5 Active, not recruiting Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
6 Active, not recruiting S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Biological: pegfilgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
7 Recruiting A Study of LY2940680 in Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: LY2940680;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Placebo
8 Completed
Has Results
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: erlotinib;   Drug: sunitinib;   Drug: placebo
9 Active, not recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: sargramostim
10 Completed
Has Results
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Chemotherapy-Induced Thrombocytopenia;   Non-Small Cell Lung Cancer;   Cancer;   Lung Neoplasms;   Oncology;   Solid Tumors;   Thrombocytopenia
Interventions: Biological: Romiplostim;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Cisplatin
11 Completed Non-small Cell Lung Cancer Registry
Conditions: Non-Small-Cell Lung Cancer;   Pleural Effusion, Malignant
Intervention: Drug: zoledronic acid
12 Recruiting A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anthracycline-based chemotherapy;   Drug: pertuzumab [Perjeta];   Drug: taxane;   Drug: trastuzumab [Herceptin];   Drug: trastuzumab emtansine [Kadcyla]
13 Active, not recruiting Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: Non-Hodgkins Lymphoma;   B-cell Lymphoma;   Waldenstrom's Macroglobulinemia;   Marginal Zone Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Primary Central Nervous System Lymphoma
Intervention: Drug: Ublituximab
14 Active, not recruiting Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Condition: Kidney Cancer
Interventions: Biological: bevacizumab;   Biological: recombinant interferon alfa
15 Recruiting A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: LY2875358;   Drug: Erlotinib
16 Terminated Combination Chemotherapy in Treating Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Biological: filgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride
17 Active, not recruiting
Has Results
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab
18 Completed
Has Results
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Biological: Cetuximab;   Biological: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
19 Active, not recruiting Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: ixabepilone;   Biological: bevacizumab;   Other: questionnaire administration;   Other: laboratory biomarker analysis
20 Recruiting S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years